Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Hack

Showing results (141-150 of 149) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 149 results.
Geburtshilfe Und Frauenheilkunde|May 1, 2024
Correction: Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace StudyCarolin C Hack, Nicolai Maass, Bahriye Aktas, et al.
Breast (Edinburgh, Scotland)|January 21, 2020
Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patientsC C Hack, L Häberle, S Y Brucker, et al.
European Journal of Cancer (Oxford, England : 1990)|April 22, 2018
Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM studyN Nabieva, T Fehm, L Häberle, et al.
Integrative Cancer Therapies|September 16, 2016
Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM StudyCarolin C Hack, Peter A Fasching, Tanja Fehm, et al.
Breast Cancer Research and Treatment|April 2, 2026
Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trialManuel Hörner, Lara M Tretschock, Nelson John, et al.
Breast Cancer Research and Treatment|January 4, 2019
Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancerMarius Wunderle, Jutta Pretscher, Sara Y Brucker, et al.
NPJ Breast Cancer|April 11, 2026
PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registryManuel Hörner, Andreas Hartkopf, Nelson John, et al.
Geburtshilfe Und Frauenheilkunde|February 16, 2022
Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) - Part 1 with Recommendations on Epidemiology, Screening, Diagnostics and TherapyMatthias W Beckmann, Frederik A Stübs, Martin C Koch, et al.
NPJ Breast Cancer|February 19, 2025
Lessons learned from a candidate gene study investigating aromatase inhibitor treatment outcome in breast cancerReiner Hoppe, Stefan Winter, Wing-Yee Lo, et al.
Pageof 15

Showing results (141-150 of 149) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 149 results.
Geburtshilfe Und Frauenheilkunde|May 1, 2024
Correction: Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace StudyCarolin C Hack, Nicolai Maass, Bahriye Aktas, et al.
Breast (Edinburgh, Scotland)|January 21, 2020
Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patientsC C Hack, L Häberle, S Y Brucker, et al.
European Journal of Cancer (Oxford, England : 1990)|April 22, 2018
Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM studyN Nabieva, T Fehm, L Häberle, et al.
Integrative Cancer Therapies|September 16, 2016
Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM StudyCarolin C Hack, Peter A Fasching, Tanja Fehm, et al.
Breast Cancer Research and Treatment|April 2, 2026
Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trialManuel Hörner, Lara M Tretschock, Nelson John, et al.
Breast Cancer Research and Treatment|January 4, 2019
Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancerMarius Wunderle, Jutta Pretscher, Sara Y Brucker, et al.
NPJ Breast Cancer|April 11, 2026
PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registryManuel Hörner, Andreas Hartkopf, Nelson John, et al.
Geburtshilfe Und Frauenheilkunde|February 16, 2022
Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) - Part 1 with Recommendations on Epidemiology, Screening, Diagnostics and TherapyMatthias W Beckmann, Frederik A Stübs, Martin C Koch, et al.
NPJ Breast Cancer|February 19, 2025
Lessons learned from a candidate gene study investigating aromatase inhibitor treatment outcome in breast cancerReiner Hoppe, Stefan Winter, Wing-Yee Lo, et al.
Pageof 15